Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-TrkA (Tyr490)/TrkB (Tyr516) (C35G9) Rabbit mAb 4619 x 40 µl
H R 140 Rabbit IgG
Phospho-TrkA (Tyr674/675)/TrkB (Tyr706/707) (C50F3) Rabbit mAb 4621 x 40 µl
H R 140 Rabbit IgG
TrkA (14G6) Rabbit mAb 2508 x 40 µl
H 140 Rabbit IgG
TrkB (80E3) Rabbit mAb 4603 x 40 µl
H M R 90, 140 Rabbit IgG
Trk (pan) (C17F1) Rabbit mAb 4609 x 40 µl
H M R 140 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 x 100 µl
All Goat 

Product Description

The TrkA and TrkB Antibody Sampler Kit provides an economical means to investigate the Trk family of tyrosine kinase receptors. The kit contains enough primary and secondary antibodies to perform four Western blots with each antibody.


Specificity / Sensitivity

Both total TrkA and TrkB antibodies detect endogenous levels of their respective Trk receptors and do not cross-react with related proteins. The Trk (pan) (C17F1) Rabbit mAb detects endogenous levels of total TrkA, TrkB, and TrkC proteins. Phospho-TrkA (Tyr490)/TrkB (Tyr516) (C35G9) Rabbit mAb detects endogenous levels of TrkA and TrkB only when phosphorylated at the indicated sites; this antibody may cross-react with Bcr-Abl phosphorylated at an unknown tyrosine residue. Phospho-TrkA (Tyr674/675)/TrkB (Tyr706/707) (C50F3) Rabbit mAb detects endogenous levels of TrkA and TrkB only when phosphorylated at the indicated sites; this antibody may cross-react with a protein of ~150 kDa phosphorylated at an unknown tyrosine residue.


Source / Purification

Total monoclonal antibodies are produced by immunizing animals with synthetic peptides surrounding Arg220 of human TrkA, Pro50 of human TrkB, and Tyr785 of human TrkA. Activation state monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Tyr490 of human TrkA or Tyr674/674 of human TrkA.

The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).


The phosphorylation sites are conserved between TrkA and TrkB: Tyr490 of TrkA corresponds to Tyr512 in TrkB, and Tyr674/675 of TrkA to Tyr706/707 in TrkB of the human sequence (14). TrkB is overexpressed in tumors, such as neuroblastoma, prostate adenocarcinoma, and pancreatic ductal adenocarcinoma (15). Research studies have shown that in neuroblastomas, overexpression of TrkB correlates with an unfavorable disease outcome when autocrine loops signaling tumor survival are potentiated by additional overexpression of brain-derived neurotrophic factor (BDNF) (16-18). An alternatively spliced truncated TrkB isoform lacking the kinase domain is overexpressed in Wilms’ tumors and this isoform may act as a dominant-negative regulator of TrkB signaling (17).


1.  Huang, E.J. and Reichardt, L.F. (2003) Annu Rev Biochem 72, 609-42.

2.  Segal, R.A. and Greenberg, M.E. (1996) Annu Rev Neurosci 19, 463-89.

3.  Stephens, R.M. et al. (1994) Neuron 12, 691-705.

4.  Marsh, H.N. et al. (2003) J Cell Biol 163, 999-1010.

5.  Reuther, G. W. et al. (2000) Mol. Cell. Biol. 20, 8655-8666.

6.  Obermeier, A. et al. (1993) EMBO J 12, 933-41.

7.  Obermeier, A. et al. (1994) EMBO J 13, 1585-90.

8.  Arevalo, J.C. et al. (2001) Oncogene 20, 1229-34.

9.  Greco, A. et al. (1997) Genes Chromosomes Cancer 19, 112-23.

10.  Pierotti, M.A. and Greco, A. (2006) Cancer Lett 232, 90-8.

11.  Lagadec, C. et al. (2009) Oncogene 28, 1960-70.

12.  Greco, A. et al. (2010) Mol Cell Endocrinol 321, 44-9.

13.  Ødegaard, E. et al. (2007) Hum Pathol 38, 140-6.

14.  Huang, E.J. and Reichardt, L.F. (2003) Annu Rev Biochem 72, 609-42.

15.  Geiger, T.R. and Peeper, D.S. (2005) Cancer Res 65, 7033-6.

16.  Han, L. et al. (2007) Med Hypotheses 68, 407-9.

17.  Aoyama, M. et al. (2001) Cancer Lett 164, 51-60.

18.  Desmet, C.J. and Peeper, D.S. (2006) Cell Mol Life Sci 63, 755-9.


Entrez-Gene Id 4914, 4915, 4916
Swiss-Prot Acc. P04629, Q16620, Q16288


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.